Panel Discussion | Devices in Heart Failure

Sunday, March 8, 2026

10:59 AM - 11:22 AM EST

Location: Georgetown

Moderator(s)

Phillip Adamson, MD

Chief Medical Officer
CVRx
Austin, Texas, United States

Disclosure(s): Abbott Labs: Stock-publicly held company (excluding mutual/index funds) (Ongoing); CVRx: Employee (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)
Navin K. Kapur, MD, FSCAI, FAHA, FACC

Professor of Medicine
Tufts Medical Center
Boston, Massachusetts, United States

Disclosure(s): Abiomed / Johnson & Johnson: Employee (Ongoing)
PL

Phillip H. Lam, MD

Advanced Heart Failure Cardiologist
MedStar Health

Disclosure(s): No financial relationships to disclose

Panel Discussant(s)

Daniel Burkhoff, MD, PhD

Director: Heart Failure, Hemodynamics and MCS Research
Cardiovascular Research Foundation
New York, New York, United States

Disclosure(s): Abiomed / Johnson & Johnson: Consulting Fees (e.g., advisory boards) (Ongoing); OrchestraBiomed: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)
Marat Fudim, MD

Associate Professor
Duke

Disclosure(s): Bayer HealthCare: Consulting Fees (e.g., advisory boards) (Ongoing)
Zvonimir Krajcer, MD

PVD program director, Editor-in Chief-THI Journal
Texas Heart Center for Cardiovascular Care at Texas Heart Institute
Houston, Texas, United States

Disclosure(s): Anaxiom Corporation: Consulting Fees (e.g., advisory boards) (Ongoing); Second Heart Assist, Inc.: Stock-privately held company (Ongoing); Taurus Vascular: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)
JoAnn Lindenfeld, MD

Director, Heart Failure and Transplantation
Vanderbilt University
Nashville, Tennessee, United States

Disclosure(s): Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); AbioMed: Consulting Fees (e.g., advisory boards) (Ongoing); Alleviant Medical: Consulting Fees (e.g., advisory boards) (Ongoing); AskBio: Consulting Fees (e.g., advisory boards) (Ongoing); Axon: Consulting Fees (e.g., advisory boards) (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing); Cordio: Consulting Fees (e.g., advisory boards) (Ongoing); CVRx: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Lifesciences: Consulting Fees (e.g., advisory boards) (Ongoing); Intershunt,: Consulting Fees (e.g., advisory boards) (Ongoing); Kestra: Consulting Fees (e.g., advisory boards) (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); Merck Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing); OrchestraBiomed: Consulting Fees (e.g., advisory boards) (Ongoing); Vectorious: Consulting Fees (e.g., advisory boards) (Ongoing); Volumetrix: Consulting Fees (e.g., advisory boards) (Ongoing); VWave: Consulting Fees (e.g., advisory boards) (Ongoing); Whiteswell: Consulting Fees (e.g., advisory boards) (Ongoing)
Stanton J. Rowe, PhD

CEO
Nidus Biomedical
Irvine, California, United States

Disclosure(s): No financial relationships to disclose
James Udelson, MD

Chief, Division of Cardiology
Tufts Medical Center
Boston, Massachusetts, United States

Disclosure(s): Alleviant: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); FIRE1: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Reprieve: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)
Sandip Zalawadiya, MD

Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, Tennessee, United States

Disclosure(s): Endotronix: Consulting Fees (e.g., advisory boards) (Ongoing); Vectorious Medical: Consulting Fees (e.g., advisory boards) (Ongoing)

Disclosure(s):

Phillip Adamson, MD: Abbott Labs: Stock-publicly held company (excluding mutual/index funds) (Ongoing); CVRx: Employee (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)

Navin K. Kapur, MD, FSCAI, FAHA, FACC: Abiomed / Johnson & Johnson: Employee (Ongoing)

Phillip H. Lam, MD: No financial relationships to disclose

Daniel Burkhoff, MD, PhD: Abiomed / Johnson & Johnson: Consulting Fees (e.g., advisory boards) (Ongoing); OrchestraBiomed: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)

Marat Fudim, MD: Bayer HealthCare: Consulting Fees (e.g., advisory boards) (Ongoing)

Zvonimir Krajcer, MD: Anaxiom Corporation: Consulting Fees (e.g., advisory boards) (Ongoing); Second Heart Assist, Inc.: Stock-privately held company (Ongoing); Taurus Vascular: Consulting Fees (e.g., advisory boards) (Ongoing), Stock-publicly held company (excluding mutual/index funds) (Ongoing)

JoAnn Lindenfeld, MD: Abbott Labs: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); AbioMed: Consulting Fees (e.g., advisory boards) (Ongoing); Alleviant Medical: Consulting Fees (e.g., advisory boards) (Ongoing); AskBio: Consulting Fees (e.g., advisory boards) (Ongoing); Axon: Consulting Fees (e.g., advisory boards) (Ongoing); Boston Scientific: Consulting Fees (e.g., advisory boards) (Ongoing); Cordio: Consulting Fees (e.g., advisory boards) (Ongoing); CVRx: Consulting Fees (e.g., advisory boards) (Ongoing); Edwards Lifesciences: Consulting Fees (e.g., advisory boards) (Ongoing); Intershunt,: Consulting Fees (e.g., advisory boards) (Ongoing); Kestra: Consulting Fees (e.g., advisory boards) (Ongoing); Medtronic: Consulting Fees (e.g., advisory boards) (Ongoing); Merck Pharmaceuticals: Consulting Fees (e.g., advisory boards) (Ongoing); OrchestraBiomed: Consulting Fees (e.g., advisory boards) (Ongoing); Vectorious: Consulting Fees (e.g., advisory boards) (Ongoing); Volumetrix: Consulting Fees (e.g., advisory boards) (Ongoing); VWave: Consulting Fees (e.g., advisory boards) (Ongoing); Whiteswell: Consulting Fees (e.g., advisory boards) (Ongoing)

Stanton J. Rowe, PhD: No financial relationships to disclose

James Udelson, MD: Alleviant: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); FIRE1: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing); Reprieve: Consulting Fees (e.g., advisory boards) (Ongoing), Grant/Research Support (Ongoing)

Sandip Zalawadiya, MD: Endotronix: Consulting Fees (e.g., advisory boards) (Ongoing); Vectorious Medical: Consulting Fees (e.g., advisory boards) (Ongoing)